-transparent.png){kind=logo}
A specific radioimmunoassay (RIA) for the determination of the new short-acting water soluble imidazo-1,4-benzodiazepine, midazolam, directly in plasma has been developed. Employing 3H-midazolam as the radioligand and a rabbit antiserum to a diazo conjugate of 5'-aminomidazolam and albumin, the method has a limit of sensitivity of 2 ng/ml of midazolam using a 20 microliters sample of plasma. The intra- and inter-assay coefficients of variation ranged from 4 to 7% and 13 to 15%, respectively. The specificity of the RIA was established by demonstrating good agreement with both EC-GC and GC-MS procedures in the analysis of multiple clinical plasma samples. The utility of the RIA for the pharmacokinetic evaluation of midazolam is illustrated with plasma concentration profiles of the drug obtained in subjects who had received midazolam intravenously, intramuscularly and orally.
R Dixon, and
R Lucek, and
D Todd, and
A Walser
November 1972,
The Annals of occupational hygiene,
R Dixon, and
R Lucek, and
D Todd, and
A Walser
May 1975,
Clinical pharmacology and therapeutics,
R Dixon, and
R Lucek, and
D Todd, and
A Walser
December 1985,
Methods and findings in experimental and clinical pharmacology,
R Dixon, and
R Lucek, and
D Todd, and
A Walser
January 1973,
Clinical pharmacology and therapeutics,
R Dixon, and
R Lucek, and
D Todd, and
A Walser
September 1976,
Current therapeutic research, clinical and experimental,
R Dixon, and
R Lucek, and
D Todd, and
A Walser
March 1979,
Investigative urology,
R Dixon, and
R Lucek, and
D Todd, and
A Walser
March 1994,
Journal of pharmaceutical sciences,
R Dixon, and
R Lucek, and
D Todd, and
A Walser
April 1971,
Arzneimittel-Forschung,
R Dixon, and
R Lucek, and
D Todd, and
A Walser
January 1974,
Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
R Dixon, and
R Lucek, and
D Todd, and
A Walser
December 1977,
European journal of clinical pharmacology,
